RESEARCH PAPER
Analysis of Acinetobacter baumannii resistance patterns in patients with chronic obstructive pulmonary disease (COPD) in terms of choice of effective empiric antibiotic therapy
 
More details
Hide details
1
Laboratory of Microbiology, Masovian Specialistic Hospital in Radom, Radom, Poland
2
Pope John II State School of Higher Education in Biała Podlaska, Biała Podlaska, Poland
3
Chair and Department of Jaw Orthopaedics, Medical University in Lublin, Lublin, Poland
CORRESPONDING AUTHOR
Aneta Grochowalska   

Laboratory of Microbiology, Masovian Specialistic Hospital in Radom, Radom, Poland
 
Ann Agric Environ Med. 2017;24(2):307–311
KEYWORDS
ABSTRACT
Introduction:
Multi-resistant Acinetobacter baumannii isolated from patients has become one of the most hazardous pathogens in health care settings. The aim of the study was to analyze pneumonia caused by Acinetobacter baumannii in patients hospitalized because of exacerbation of chronic obstructive pulmonary diseases (COPD), who were admitted to the Pulmonology Ward of the Masovian Specialistic Hospital in Radom (MSS). The incidence and drug sensitivity of these non-fermenting rods were evaluated, and compliance with antimicrobial procedure with the algorithm of the guidelines in applicable recommendations, was estimated. This should result in determining the local patterns of resistance and verifying therapeutic procedures in accordance with the assumptions of hospital antibiotic policy. In addition, the study examined the effectiveness of empiric and targeted therapy according to the clinical condition of the patient, and the eradication of A. baumannii, in comparison with the aggravating factors of the patient.

Material and Methods:
The retrospective study included 90 patients with exacerbation of COPD whose etiological factor of infection was A. baumannii, hospitalized in the Department of Pulmonology (MSS) in 2012–2016.

Results:
Studies were conducted on 90 patients with COPD exacerbation from which A. baumannii was isolated. Co-infections with other bacterial species among 41 patients were additionally noted. The majority of A. baumannii strains showed a high resistance (90%) to fluoroquinolones, ceftazidime, piperacillin/tazobactam. For strains causing a co-infection, drug resistance was successively 44–56%, 44%, 44%. All of patients received empirical therapy. The most commonly used drug was amoxicillin with a clavulanic acid, often combined with fluoroquinolone. This type of therapy was effective among 10% of patients. The mortality in this group was determined at 29%. Among 79% of patients with COPD, a targeted therapy was performed which proved to be effective in 58% of treated cases by susceptibility testing. The highest efficacy was observer after the use of colistin and carbapenems.

Conclusions:
In the performed study, the infections caused by multi-resistant Acinetobacter baumannii, were observed in COPD, which should be taken into consideration in choosing empirical antibiotic therapy. Simultaneously, the local resistance patterns of multi-drug-resistant (MDR) Gram-negative strains co-infecting COPD should be considered in empirical treatment. Moreover, both additional clinical complication and co-infections contribute to a more severe course of diseases. In this study, the mortality percent exceeded 29%.

 
REFERENCES (24)
1.
Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006; 27(2): 397–412.
 
2.
Oliynyk O, Doroshenko M, Slifirczyk A. Evaluation of calcium homeostasis in patients treated in Ternopil University Hospital for chronic obstructive pulmonary disease. Health Problems of Civilization. 2016; 10(4): 60–64.
 
3.
Stoleski S, Minov J, Karadzinska-Bislimovska J, Mijakoski D. Chronic obstructive pulmonary disease in never-smoking dairy farmers. Open Respir Med J. 2015; 31;9: 59–66.
 
4.
Szczyrek M, Krawczyk P, Milanowski J, Jastrzębska I, Zwolak A, Daniluk J. Chronic obstructive pulmonary disease in farmers and agricultural workers – an overview. Ann Agric Environ Med. 2011; 18(2): 310–313.
 
5.
Donaldson GC, Wedzicha JA. Review series, COPD exacerbations 1: Epidemiology. Thorax 2006; 61: 164–168.
 
6.
Lin SH, Kuo PH, Hsueh PR, Yang PC, Kuo SH. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology. 2007; 12(1): 81–7.
 
7.
Noweta K, Frankowska M, Grzelewska-Rzymowska. Exacerbations of chronic obstructive pulmonary disease and the role of sputum bacteriological examination. Pneumonol Alergol Pol. 2006; 74(4): 396–402.
 
8.
Nseir S, Ader F. Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria. Curr Opin Pulm Med. 2008; 14(2): 95–100.
 
9.
Tripathi PC, Gajbhiye SR, Agrawal GN. Clinical and antimicrobial profile of Acinetobacter spp.: An emerging nosocomial superbug. Adv Biomed Res. 2014; 9;3: 13.
 
10.
Mastoraki A, Douka E, Kriaras I, Stravopodis G, Saroglou G, Geroulanos S. Preventing strategy of multidrug-resistant Acinetobacter baumannii susceptible only to colistin in cardiac surgical intensive care units. Eur J Cardiothorac Surg. 2008; 33(6): 1086–90.
 
11.
Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2007; 51(9): 3413–5.
 
12.
Ye D, Shan J, Huang Y, Li J, Li C, Liu X, et al. A gloves-associated outbreak of imipenem-resistant Acinetobacter baumannii in an intensive care unit in Guangdong, China. BMC Infect Dis. 2015; 11;15: 179.
 
13.
Shete VB, Ghadage DP, Muley VA, Bhore AV.Lung India. Multi-drug resistant Acinetobacter ventilator-associated pneumonia. 2010; 27(4): 217–20.
 
14.
Townsend J, Park AN, Gander R, Orr K, Arocha D, Zhang S, Greenberg DE. Acinetobacter infections and outcomes at an academic medical center: a disease of long-term care. Open Forum Infect Dis. 2015; 12;2(1): ofv023.
 
15.
Hryniewicz W, Ozorowski T, et al. Rekomendacje diagnostyki, terapii i profilaktyki antybiotykowej zakażeń w szpitalu. Narodowy Program Ochrony Antybiotyków. 2015. www.antybiotyki.edu.pl.
 
16.
Odewale G, Adefioye OJ, Ojo J, Adewumi FA, Olowe OA. Multidrug Resistance of Acinetobacter Baumannii in Ladoke Akintola University Teaching Hospital, Osogbo, Nigeria. Eur J Microbiol Immunol (Bp). 2016; 29;6(3): 238–243.
 
17.
Osei Sekyere J. Current State of Resistance to Antibiotics of Last-Resort in South Africa: A Review from a Public Health Perspective. Front Public Health. 2016; 30;4: 209.
 
18.
Nakou A, Papaparaskevas J, Diamantea F, Skarmoutsou N, Poly chrono-poulos V, Tsakris A. A prospective study on bacterial and atypical etiology of acute exacerbation in chronic obstructive pulmonary disease. Future Microbiol. 2014; 9(11): 1251–60.
 
19.
Keeley AJ, Beeching NJ, Stott KE, Roberts P, Watson AJ, Beadsworth MB. Clostridium difficile : A healthcare-associated infection of unknown significance in adults in sub-Saharan Africa. Malawi Med J. 2016; 28(2): 66–69.
 
20.
Rodriguez C, Taminiau B, Korsak N, Avesani V, Van Broeck J, Brach P, Delmée M, Daube G. Longitudinal survey of Clostridium difficile presence and gut microbiota composition in a Belgian nursing home. BMC Microbiol. 2016; 1;16(1): 229.
 
21.
Li XJ, Li Q, Si LY, Yuan QY. Bacteriological differences between COPD exacerbation and community-acquired pneumonia. Respir Care. 2011; 56(11): 1818–24.
 
22.
Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2006; 1;43 Suppl 2: S100–5.
 
23.
Mu X, Wang N, Li X, Shi K, Zhou Z, Yu Y, et al. The Effect of Colistin Resistance-Associated Mutations on the Fitness of Acinetobacter baumannii. Front Microbiol. 2016; 1;7: 1715.
 
24.
Rossi F, Girardello R, Cury AP, Gioia TS, Almeida JN Jr, Duarte AJ. Emergence of colistin resistance in the largest university hospital complex of São Paulo, Brazil, over five years. Braz J Infect Dis. 2016; 7. pii: S1413–8670(16)30442–1.
 
eISSN:1898-2263
ISSN:1232-1966